By Alberto Alerigi SAO PAULO (Reuters) -Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide ...

The medical director of the NHS has warned of the side effects of weight loss drugs after figures revealed the number of deaths associated with the jabs ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Spring has nearly sprung and round two of the Inflation Reduction Act (IRA)’s negotiation period has begun. | All of the ...

Last month, the U.S. Food and Drug Administration (the “FDA”) announced in a Declaratory Order the resolution of the shortage of semaglutide ...

The company has maintained its global diabetes value market share over the past year at 33.7%, fueled by Rybelsus, Ozempic and Victoza, putting up a strong performance. In 2024, Novo Nordisk’s ...

Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 billion between 2019 and 2023, a U.S. government watchdog's report showed this ...

Its portfolio includes insulin analogs, GLP-1 receptor agonists, and oral antidiabetic drugs like Rybelsus, Ozempic, and Tresiba. Novo Nordisk A/S (NYSE:NVO) delivered exceptional financial ...

Nevertheless, Novo Nordisk beat fourth-quarter earnings and sales estimates. Its diabetes drugs Ozempic and Rybelsus and obesity drug Wegovy are performing well, fueled by increasing demand.

(Learn more with Ozempic For Weight Loss: How It Works, Side Effects & More) Ozempic is one brand name for the drug semaglutide from the pharmaceutical manufacturer Novo Nordisk. It’s FDA ...

the active ingredient of Novo Nordisk's (NOVOb.CO), opens new tab blockbuster diabetes and weight-loss drug Ozempic, Hypera's chief executive said on Friday. The patent protection for semaglutide ...